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Abstract.  Several cell types display binding sites for 
[~zSI]urokinase  (Vassalli,  J.-D.,  D.  Baccino, D.  Belin. 
1985. J.  Cell Biol.  100:86-92)  which in certain cases 
are occupied with endogenous urokinase.  These sites 
appear to focus urokinase at cell surfaces and hence 
may participate in tissue matrix destruction and cell 
invasion.  Recently P611~inen et al.  (1987)  demonstrated 
that the cell surface urokinase of human fibroblasts 
and fibrosarcoma cells is deposited underneath the 
cells in strands,  apparently at sites of cell-to- 
substratum contact. Here, using immunofluorescence 
double labeling,  we show that the urokinase strands 
present on human foreskin fibroblasts are colocalized 
with strands  of vinculin, an intracellular actin-binding 
protein that is deposited at cell-to-substratum focal 
adhesion sites.  Thus, this indicates linkage of the plas- 
minogen/plasmin system both to sites of cell adhesion 
and to the cytoskeleton. The urokinase strands on HT 
1080  fibrosarcoma cells are more numerous and have 
shapes that are more tortuous than those on normal 
fibroblasts.  In intact HT  1080  cells, colocalized vincu- 
lin strands are obscured by an intense background of 
soluble vinculin but are apparent on isolated ventral 
plasma membranes.  Certain properties of the uro- 
kinase strands  suggest that they are related to the 
[~25I]urokinase-binding sites that have been described 
by several groups:  (a)  incubating fibroblasts with dexa- 
methasone for 48 h  or at pH 3 at 5~  for 10 min 
greatly decreases the number and intensity of the uro- 
kinase strands;  (b)  strands  reappear when 
glucocorticoid-treated cells are incubated with exoge- 
nous 54-kD (but not 35-kD)  urokinase,  and this pro- 
cess is inhibited by a previously described  16-amino 
acid peptide that blocks [~25I]urokinase  binding to the 
cells. 
T 
HE plasminogen activator urokinase has been impli- 
cated as a mediator of tissue remodeling and cell inva- 
sion in several normal processes (e.g., mammary gland 
involution [20]  and angiogenesis  [6]),  and also  in  certain 
pathological states (12, 15). 
A substantial body of evidence links tumor cell secretion 
of urokinase to tumor-mediated destruction of tissue matrices 
and  tumor  cell  invasion.  Although  there  are  exceptions, 
generally tumor cells produce urokinase in  much greater 
amounts than do normal cells (32). Antiurokinase antibody 
inhibits Hep3 human epidermoid carcinoma cells from me- 
tastasizing in chicken embryos (19) and penetrating human 
placental amnion membranes (18). Both antiurokinase anti- 
body and  the  urokinase inhibitor protease nexin I  inhibit 
HT  1080 human fibrosarcoma cell destruction of vascular 
smooth muscle extracellular matrix (5). A monoclonal anti- 
body against the avian counterpart of urokinase inhibits the 
destruction of chick fibroblast extracellular matrix by Rous 
sarcoma  virus-transformed  chick  fibroblasts,  and  causes 
these transformed cells to assume normal morphology (28). 
It has been demonstrated that monocytes have urokinase 
"receptors" on their surfaces that do not mediate the inter- 
nalization of urokinase but hold the enzyme at the cell sur- 
face (29). These binding sites bind the 54-kD but not the 35- 
kD form of the enzyme. Similar sites have been detected on 
normal fibroblasts and  several types of tumor cells (3,  7). 
Blasi et ai. (7) have identified a  16-amino acid sequence at 
the NH2 terminus of the 54-kD urokinase light chain that 
recognizes the binding sites on A431 cells. The sites are par- 
tially or completely occupied with endogenous urokinase on 
normal fibroblasts and tumor cells, respectively (4, 27).  In 
the case of monocytes, the sites become occupied with en- 
dogenous urokinase after activation of these cells (26). Im- 
munofluorescence detection of urokinase on monocytes (29) 
and A431 carcinoma cells (27) suggests that this antigen is 
relatively diffusely distributed on the surfaces of these cells. 
Recently,  P611~inen et  al.  (22)  reported that  urokinase on 
fibroblasts and fibrosarcoma cells is concentrated in fibers 
that are located beneath the cells, apparently at sites of cell 
contact with  the  substratum.  Here we show that the uro- 
kinase immobilized on human foreskin fibroblasts is concen- 
trated in arrays of strands and that many of these are colocal- 
ized  with  strands  of vinculin,  a  protein  that  links  focal 
adhesion sites with the cytoplasmic actin-containing micro- 
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binding sites that give rise to these arrays in certain, but not 
all respects resemble the urokinase-binding sites previously 
detected  in binding studies carried Out with radioiodinated 
urokinase (3,  26,  29). 
Materials and Methods 
Materials 
Human 35-kD urokinase was purchased from Collaborative Research, Inc., 
Waltham, MA. Human 54-kD urokinase and goat antiurokinase IgG were 
purchased  from  American Diagnostica  Inc.  (Greenwich,  CT).  Affinity 
purified rabbit antiurokinase IgG was obtained as previously described (13). 
Rabbit antivinculin serum was a  gift from Dr.  Gary C.  Rosenfeld of the 
University of  Texas Medical Center at Houston. Rabbit antithrombospondin 
IgG was a gift from Dr. Barry W. Festoff  of the Kansas University Medical 
Center at Kansas City.  Rabbit antifibronectin IgG and rhodamine-conju- 
gated goat anti-rabbit IgG were purchased from ICN K&K Laboratories 
Inc., Plainview,  NY. Fluorescein-conjugated swine anti-goat IgG and soy- 
bean trypsin inhibitor were obtained from Boehringer Mannheim Diagnos- 
tics, Inc., Houston, TX and fluorescein-conjugated  goat anti-rabbit IgG was 
from Sigma Chemical Co., St.  Louis, MO.  We used 30-mm cell culture 
dishes (Falcon 3001; Becton Dickinson and Co.,  Mountain View,  CA). 
DME was purchased from Hazleton Systems, Inc., Aberdeen, MD. Penicil- 
lin-streptomycin solution and FBS were obtained from Irvine Scientific, 
Santa Ana, CA. Trypsin and L-glutamine were purchased from KC Biologi- 
cal Inc., Lenexa, KS. Selenous acid was obtained from Aldrich Chemical 
Co., Milwaukee, WI, and paraformaldehyde and DMSO were from Fisher 
Scientific Co.,  Pittsburgh,  PA.  RIA-grade BSA,  dexamethasone, human 
transferrin, saponin, and diisopropylphosphofluoridate were from Sigma 
Chemical Co. The 16-mer peptide corresponding to the urokinase-binding 
site  sequence  (G-T-C-V-S-N-K-Y-F-S-N-I-H-W-C-N)  was  synthesized by 
Biosearch, San Rafael, CA. 
Cell Culture 
Unless otherwise noted, human foreskin fibroblasts (HF)  ~  ceils and human 
HT 1080 fibrosarcoma cells were grown in DME supplemented with FBS 
(4% for HF cells and 10% for HT 1080 cells) and L-glutamine as previously 
described (25).  Culture media contained 200 U/ml penicillin G  and 200 
Ixg/ml streptomycin sulfate.  Cultures  were maintained in a  5%  CO2 at- 
mosphere at 37~  Unless indicatr..d otherwise, cells were seeded at 2  ￿ 
104 (HF) or 1  ￿  104 (HT  1080) cells/dish, grown for 24 h in serum-con- 
taining medium, and then incubated in serum-free medium for at least 2 h 
before immunofluorescence or [~251]urokinase-binding experiments. 
Dexamethasone Treatment 
HF  cells  (at  2  x  104/ml) were  seeded  in  30-ram  dishes  in  serum- 
containing medium. After 12 h the cells were washed twice with and then 
cultured for 48  h  in serum-free DME, 0.15 p.g/rnl dexamethasone, 0.1% 
BSA,  2  tag/rnl  human transferrin, and 4  pg/ml  selenous acid (ATS-DX 
medium). In one experiment, confuent HF cells were grown in serum-free 
DME containing t-glutamine and dexamethasone for 12 h, passaged with 
0.05%  trypsin-containing dexamethasone, and plated in ATS-DX  medium 
containing 10 I~g/ml soybean trypsin inhibitor. After 5  h, the cells were 
washed twice with and incubated in ATS-DX  medium for 48 h. 
Immunofluorescence Labeling of Urokinase 
and Vinculin 
Immunofluorescence  labeling was done according to the procedure ofM. C. 
Willingham and I. Pastan (31). The cells were fixed on ice with 3.7% para- 
formaldehyde in  PBS.  Treatment of the cells with acidic buffer (0.1 M 
glycine-HCl, pH 3, for 10 min), attempts to reload the urokinase-binding 
sites with 54- or 35-kD urokinase, and competition by the 16-mer peptide 
were all carried out on ice before cell fixation. Nonspecific antibody binding 
was blocked by incubating the cells at room temperature with  1%  BSA. 
1. Abbreviations  used in this paper:  ATS-DX medium, serum-free DME, 
0.15 p.g/ml dexamethasone, 0.1% BSA, 2  pg/ml human transferrin, and 4 
lag/ml selenous acid; HF, human foreskin fibroblasts. 
Figure 1. Immunofluorescence localization of urokinase on the sur- 
faces  of fixed human  foreskin  fibroblasts.  Coverslips  containing 
fixed fibroblasts were incubated with affinity-purified rabbit anti- 
urokinase  IgG  (A  and  B)  or  nonimmune  IgG  (C)  followed  by 
fluorescein-labeled goat anti-rabbit IgG.  Bars,  20  I.tm. 
Fixed cells were incubated for 45 min at room temperature with immune 
or nonimmune lgG (30 p.g/ml) and for 15 min at room temperature with 
fluorochrome antibody conjugate (50 ktg/ml). In the case of vinculin local- 
ization, 0.1% saponin was added to all the reagents to permeabilize the cells. 
Immunofluorescence staining of vinculin was always performed after stain- 
ing of urokinase to avoid permeation of antiurokinase IgG inside the cells. 
All coverslips were mounted in 0.05  M Tris-Cl, 50%  glycerol, 0.02%  so- 
dium azide (pH 8.1) and observed with a microscope (E. Leitz Inc., Rock- 
leigh, N  J) equipped with epifluorescence and a Fluoreszenz 40:1.3  oil im- 
mersion objective. 
The Journal  of Cell Biology,  Volume 106, 1988  1242 Figure 2. Urokinase and vinculin of fixed human foreskin fibroblasts detected by double immunofluorescence labeling. Goat antiurokinase 
IgG and fluorescein-labeled swine anti-goat IgG were applied before permeabilization of the cells with 0.1% saponin. The permeabilized 
cells were treated with rabbit antivinculin serum and rhodamine-conjugated goat anti-rabbit IgG. (A and C) Distribution of urokinase on 
the cell surface as indicated by fluorescein fluorescence. (B and D) Distribution of vinculin as indicated by rhodamine fluorescence. Control 
cells, stained for  just vinculin or  just urokinase, demonstrated no spillover between rhodamine and fluorescein filters. Arrows indicate where 
the relative intensities of the vinculin and urokinase strands have shifted. Bars, 20 ~tm. 
Results 
Foreskin fibroblasts were fixed without permeabilization, in- 
cubated with rabbit antiurokinase antibody, followed by fluo- 
rescein-labeled goat anti-rabbit IgG, and examined by epi- 
fluorescence microscopy. The antiurokinase antibody stained 
fiberlike strands, arrays of which tended to outline the cell 
borders  (Fig.  1) and  resembled the  urokinase  strands  re- 
cently described by F'611~inen et al.  (22).  Occasionally the 
fluorescence formed almost continuous frames around the 
cells. When nonimmune IgG was substituted for the primary 
antibody, diffuse yellow fluorescence, also observed with the 
immune IgG, was evident, but no strands were present. The 
strands of urokinase antigen were also observed when affin- 
ity-purified rabbit antiurokinase IgG, another rabbit antiuro- 
kinase antiserum, or goat antiurokinase IgG were used as 
primary antibody. 
We were struck that the patterns of  urokinase immunofluo- 
rescence resembled published immunofluorescence patterns 
generated by staining of vinculin (14), a cytoplasmic actin- 
binding protein that is deposited in strands  at cell-to-sub- 
stratum focal adhesion sites (9). The spatial distribution of 
the urokinase and vinculin strands was investigated by dou- 
ble immunolabeling. The antivinculin antibody did not stain 
cells that had not been permeabilized (data not shown). The 
pattern of vinculin immunofluorescence in saponin-permea- 
bilized cells is shown in Fig. 2, B and D.  Much of the cell 
cytoplasm was covered by even and rather intense fluores- 
cence, consistent with findings that a  large fraction of the 
vinculin in cells is soluble (21).  In addition, characteristic 
discrete strands of  vinculin were visible at the edges. Intrigu- 
ingly, Fig. 2 demonstrates that a large fraction of the vinculin 
strands (B and D) were colocalized with strands of urokinase 
(A and C), and vice versa. All of the vinculin and urokinase 
strands were in the same plane of focus, essentially at the 
substratum (coverslip) surface. 
Examination of Fig. 2 also indicates that some urokinase 
strands lacked detectable colocalized vinculin strands, and 
some  vinculin  strands  lacked  detectable colocalized uro- 
kinase  strands.  At present  there  is  no basis  for deciding 
whether these actually represent instances of vinculin and 
urokinase strands not being colocalized or instances of the 
antigen strands being inaccessible to antibody.  In some cases, 
H6bert  and Baker Urokinase Strands  1243 Figure 3.  Distribution of urokinase on human foreskin fibmblasts before (A) and after (B) pH 3.0 treatment.  The cells were incubated 
on ice for 10 min with 0.t M glycine-HC1 (pH 3.0), rinsed with PBS three times, and fixed. Immunofluorescence staining of urokinase 
was performed  as mentioned in Fig.  1. Bars, 20 I.tm. 
arrays of vinculin and urokinase strands were offset along the 
cells, as shown in Fig. 2, C and D. These offset patterns sug- 
gest that the focal contacts had loosened at one region of the 
cell, leaving urokinase strands, and had reformed at another 
region of the cell where they had not yet become loaded with 
urokinase. 
Fragments of ventral cell surfaces that are enriched in fo- 
cal adhesion plaques can be isolated, still attached to the cul- 
ture dishes by rinsing cells after an incubation in a solution 
containing  1 mM ZnCI2 (2).  Use of this procedure on fore- 
skin fibroblasts yielded culture dish surfaces that contained 
numerous superimposed strands of urokinase and vinculin 
that were similar to those present in  intact cells (data not 
presented). 
Brief treatment of foreskin fibroblasts at pH 3 on ice ex- 
tracts urokinase from the cells and simultaneously exposes 
~50,000  previously cryptic urokinase-binding  sites (3,  4). 
This, and a similar finding made with A431 carcinoma cells 
(27), have been interpreted as evidence that pH 3 extracts en- 
dogenous urokinase from its cell surface-binding sites. Fig. 
3 shows that incubation of the fibroblasts at pH 3 for 10 min 
on  ice caused the disappearance of the urokinase strands. 
Addition of 54-kD urokinase to the cells after their incuba- 
tion at pH 3,  in general,  did not lead to the reappearance 
strands  of urokinase  immunofluorescence,  although  occa- 
sionally strands did appear which were thinner, less intense, 
and  less clearly confined  to the cell borders than the uro- 
kinase strands present on cells before pH 3 treatment (data 
not presented).  The incubation  at  reduced  pH caused the 
edges of the cells to become jagged or crenated, but the vin- 
culin fibers were not notably perturbed. 
An alternative way to deplete the endogenous urokinase is 
to  incubate  the  cells  with  cortisot  or  dexamethasone  (4). 
These glucocorticoids inhibit the synthesis and secretion of 
urokinase by a wide variety of cells (e.g., see references 17, 
30). Treatment of the foreskin cells with 0.15 IxM dexametha- 
sone for 48 h resulted in a pronounced reduction, but not vir- 
tual elimination, of the number of urokinase strands (Fig. 4). 
Incubation of these dexamethasone-treated cells with 54-kD 
urokinase  resulted  in  the  reappearance  of numerous  uro- 
kinase-containing  strands  that  resembled those present on 
cells that had not been incubated with dexamethasone. It is 
noteworthy that the urokinase immunofluorescence was not 
restored when 35-kD urokinase was used (Fig. 4). This re- 
sult was probably not caused by failure of the antibody to 
recognize  35-kD  urokinase,  because  preincubation  of the 
antibody with this form of the enzyme eliminated its stain- 
ing of cellular urokinase strands on cells that had not been 
treated with dexamethasone (data not presented). 
Blasi et al.  (7) have identified a  16-amino acid sequence 
in 54-kD urokinase that blocks the binding of ['~I]urokinase 
to A431 carcinoma cells. In our hands, this peptide, at high 
(0.1 mM) concentration, caused a 70% inhibition of specific 
binding of ['z5I]urokinase-DIP to foreskin fibroblasts:  565 
+  277 cpm with the peptide, compared to 2,000 +  222 cpm 
without the peptide (+ indicating the range of duplicate mea- 
surements). Fig. 5 shows that the peptide prevented the reap- 
pearance  of the  strands  of urokinase  on  dexamethasone- 
treated cells incubated with 54-kD urokinase. 
In an attempt to completely eliminate the urokinase im- 
munofluorescence that remained after the 48-h incubation of 
the cells with dexamethasone, the cells were incubated for 
12 h in serum-free medium containing dexamethasone, sub- 
cultured  by  trypsinization,  and  further  incubated  in  this 
medium for 48 h. This regimen resulted in the complete dis- 
appearance of urokinase-containing fibers. Brilliant dots, but 
no  strands  of urokinase  immunofluorescence appeared on 
these cells when they were incubated with 54-kD urokinase. 
Urokinase strands failed to form on these cells even when 
they were cultured  for 24 h  in the presence of this ligand. 
Numerous urokinase strands have recently been detected 
on HT 1080 fibrosarcoma cells (22). Because tumor cells in 
general  tend  to  be  less  adhesive  than  normal  anchorage- 
dependent cells and have reduced numbers of focal contacts 
(24), we sought to determine whether the urokinase strands 
on HT 1080 cells were accompanied by superimposed vincu- 
lin strands. Unlike the normal fibroblasts, HT 1080 cells that 
were stained for urokinase had a diffuse green glow, suggest- 
ing that urokinase was dispersed over the cells. In addition 
to this, the urokinase antigen present on HT 1080 cells was, 
as in the case of normal fibroblasts, distributed in discrete 
strands  (Fig.  5).  The strands  differed from those of fibro- 
The Journal of Cell Biology. Volume  106,  1988  1244 Figure 4. Disappearance of urokinase on dexamethasone-treated  cells, and reappearance of urokinase strands after incubation  of these cells 
with urokinase.  Foreskin fibroblasts were seeded in 30-mm dishes (2  ￿  104 per dish) in serum-containing  medium. After 6 h, the cells 
were washed twice with and then cultured for 48 h in serum-free medium containing 0.1% BSA, 2 gg/ml human transferrin, and 4 ~tg/ml 
selenous acid (ATS medium) without (A) or with (B-F) dexamethasone  (0.15 ~tM). Before fixation the dexamethasone-treated  cells were 
incubated for 1 h on ice in PBS containing 1% BSA plus (B) no supplement, (C) 1.3 nM 54-kD urokinase, or (D) 1.3 nM 35-kD urokinase 
In E and F, the dexamethasone-treated  cells were incubated for  15 min in 1% BSA/PBS,  1%  DMSO without  (E) and with (F) 0.1  mM 
"binding site peptide" (see Materials and Methods). 54-kD urokinase (1.3 nM final concentration) in 1% BSA/PBS was added and the cover- 
slips were incubated  for  1 h on ice before washes with PBS and fixation. Bars,  20 lam. 
blasts in that they were more numerous and twisted, and ex- 
tended inward closer to  the  centers of the  cells.  Vinculin 
strands were present in these cells but were very faint and 
were obscured by soluble vinculin. Examination of HT 1080 
ventral surfaces by double immunolabeling  clearly revealed 
vinculin strands superimposed on the strands of urokinase 
(Fig. 5). 
Discussion 
The  present  immunofluorescence study  indicates that  the 
H6bert and Baker Urokinase  Strtmds  1245 Figure 5.  Urokinase and vinculin of fixed HT 1080 whole cells and ventral surfaces. Immunofluorescence staining was performed as de- 
scribed in Fig. 2. Ventral surfaces of HT 1080 cells were rinsed in 50 mM 2-(N-morpholino)ethane sulfonic acid containing 3 mM EDTA 
and 5 mM MgCI2 (pH 6.0), incubated on ice for 2 min with the same buffer containing  1 mM ZnCI,, and then rinsed with 20-30 jets 
of PBS before fixation. This procedure yielded coverslips that contained mostly ventral cell surfaces but also some intact cells.  (.4 and 
C) Urokinase on an intact cell and ventral surfaces (arrows). (B and D) Vinculin of an intact cell and ventral surfaces (arrows). Bars, 20 Ixm. 
urokinase on the surfaces of human fibroblasts is reversibly 
bound to "receptors" that are concentrated in discrete strands 
which are deposited at sites of focal contact between the cells 
and their substratum. The urokinase-binding sites that give 
rise to the urokinase strands could be identical to the recently 
described  cell  surface-binding sites  for 54-kD  [J25I]uroki- 
nase (3,  26,  29),  because 54-kD but not  35-kD urokinase 
formed strands on dexamethasone-treated (urokinase-deplet- 
ed) cells, and because a  peptide fragment of 54-kD uroki- 
nase that blocks [~2SI]urokinase binding to cells blocked this 
strand formation. However, one observation does not suggest 
this view. 54-kD urokinase did not convincingly form strands 
on cells that  had been preincubated at pH  3  on  ice, even 
though  this  preincubation  procedure  unmasks  [J25I]uroki- 
nase-binding sites as it extracts exogenous cell surface uro- 
kinase  (3,  4).  It is possible that  (a)  even though  the only 
fibroblast urokinase-binding sites detected by immunofluo- 
rescence were clustered in strands, these clustered sites actu- 
ally represent the minority of the urokinase-binding sites, the 
rest being diffusely distributed,  and  (b) exposure to pH 3 
selectively inactivates the clustered sites. 
The urokinase  strands  were colocalized with  strands of 
vinculin,  an  intracellular  protein that is deposited at focal 
adhesion sites (9). Cells actively move about on the surfaces 
of culture dishes, a process that must entail the repeated for- 
mation and dissolution of adhesive contacts with the (tissue 
matrix) substratum (1). The localization of cell urokinase at 
focal adhesion sites indicates that the enzyme may be poised 
to participate in the release of cells from adherent substratum 
proteins.  That cells are capable of selectively hydrolyzing 
very small spots of extracellular matrix has been elegantly 
demonstrated  by  Chen  et  al.  (10).  Their  work on  virally 
transformed chick fibroblasts suggests that matrix destruc- 
tion occurs precisely at sites of cell-substratum contact that 
underlay "rosettes" of cytoplasmic vinculin. However, in this 
system a  metalloproteinase and  not plasminogen activator 
seems to be responsible for the  focal proteolysis (10). 
Whether urokinase causes extracellular matrix destruction 
and promotes cell migration by direct hydrolysis of matrix 
proteins or by activating plasminogen is an open issue. The 
fastidious specificity of urokinase suggests the latter mecha- 
nism. However, Sullivan and Quigley (28) have demonstrat- 
ed that the direct action of the avian counterpart of urokinase 
on substratum or cell surface proteins generates the charac- 
teristic  transformed  morphology of Rous  sarcoma  virus- 
transformed chick fibroblasts, and Quigley et al.  (23) have 
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fibronectin. Although high (>ttg/ml) concentrations of uro- 
kinase are required for this cleavage, the present results indi- 
cate that the local concentration of this enzyme at focal ad- 
hesion  sites  could  be  extremely  high.  The  present  work 
does not indicate whether the urokinase that is contained in 
strands  is the single-chain Cproenzyme") form or the two- 
chain form. The latter  is active.  Whether the single-chain 
form is active under certain circumstances (16) or absolutely 
requires cleavage  (by  plasmin or certain  other serine pro- 
teases) for activation  is controversial (8,  16). Cubellis et al. 
have  recently shown that single-chain urokinase that is al- 
lowed to bind to urokinase receptors on monocytes is suscep- 
tible to plasmin-mediated  cleavage  to two-chain urokinase 
(n). 
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